Novartis receives European Commission approval for
Cosentyx® (secukinumab) becomes first and only IL-17A inhibitor approved in Europe for adults with PMR,1 a common inflammatory…
#Europe #EU #EuropeanCommission #ChronicIllness #innovation #mediarelease #NovartisPharmaAG #ReimagineMedicine #SwissStockExchange:NOVN.SW
https://www.europesays.com/europe/164077/